Health technology assessment of gene therapies for neuromuscular diseases.

Lim Moore*

Department of Neuroscience, Oxford University Global Surgery Group, Oxford, UK

Introduction

Gene therapies have emerged as a promising treatment option for various neuromuscular diseases, which are a group of disorders that affect the nerves that control voluntary muscles. The goal of gene therapy is to correct or replace a defective or missing gene with a functional one, thus restoring normal gene expression and function. However, the development and assessment of gene therapies for neuromuscular diseases pose unique challenges, including the complexity of the underlying biology, the need for specialized delivery systems, and the potential risks associated with gene editing.

Health Technology Assessment (HTA) is a systematic and comprehensive evaluation of the clinical effectiveness, safety, and cost-effectiveness of health technologies, including gene therapies. HTA aims to provide decision-makers with the best available evidence to inform policy and practice, and to optimize the allocation of scarce resources. In the case of gene therapies for neuromuscular diseases, HTA can help to determine whether these treatments are likely to provide meaningful benefits to patients, how they compare to existing treatments, and whether they represent good value for money [1].

Clinical effectiveness is a key component of HTA, as it evaluates whether a health technology works as intended and achieves the desired outcomes. For gene therapies for neuromuscular diseases, clinical effectiveness can be assessed by measuring improvements in muscle strength, function, and quality of life. However, assessing clinical effectiveness is challenging for several reasons. First, neuromuscular diseases are rare and heterogeneous, with a wide range of clinical manifestations and disease severity. Second, gene therapies may have long-term effects that are difficult to measure over short-term clinical trials. Third, the natural history of some neuromuscular diseases may be unpredictable or variable, making it difficult to distinguish between treatment effects and disease progression [2].

Safety is another important aspect of HTA, as it evaluates the potential harms and risks associated with a health technology. For gene therapies for neuromuscular diseases, safety can be assessed by monitoring adverse events, such as immune reactions, infections, or toxicity. Gene therapies also carry unique risks, such as the potential for off-target effects, unintended gene editing, or insertional mutagenesis. Therefore, safety assessments for gene therapies require careful consideration of the potential risks and benefits, as well as the ethical and regulatory frameworks governing gene editing.

Cost-effectiveness is a critical component of HTA, as it evaluates whether a health technology provides good value for money compared to existing treatments or alternative uses of resources. For gene therapies for neuromuscular diseases, cost-effectiveness can be assessed by estimating the costs of treatment, including the cost of the gene therapy, the cost of delivery, and the cost of monitoring and follow-up. Cost-effectiveness also requires consideration of the potential long-term benefits and costs of treatment, such as the potential for reduced hospitalization, rehabilitation, or caregiver burden. However, the high upfront costs of gene therapies pose challenges to assessing their cost-effectiveness, as these treatments may require significant investment upfront but offer potential long-term benefits [3].

Moreover, HTA for gene therapies in neuromuscular diseases should also consider the ethical and societal implications of these treatments. Gene therapies involve manipulating the genetic makeup of individuals, raising questions about consent, privacy, and equity. It is important to ensure that individuals have access to comprehensive information and counseling regarding the potential risks, benefits, and long-term implications of gene therapies. Ethical considerations should also address issues such as the fair distribution of gene therapies, affordability, and the prioritization of treatment for patients with the greatest need [4].

Additionally, HTA should account for the scalability and sustainability of gene therapies for neuromuscular diseases. Currently, gene therapies are primarily developed for rare diseases with a clear genetic cause, but the application of gene therapies may expand to more common neuromuscular disorders in the future. As gene therapies become more widely adopted, the healthcare system must be prepared to handle the increased demand and ensure the availability of specialized facilities, healthcare professionals, and supportive services for patients undergoing gene therapy [5].

Conclusion

HTA plays a crucial role in evaluating the clinical effectiveness, safety, and cost-effectiveness of gene therapies for neuromuscular diseases. While there are unique challenges in assessing these therapies, promising results from clinical trials have demonstrated their potential to improve muscle

***Correspondence to:** Lim Moore. Department of Neuroscience, Oxford University Global Surgery Group, Oxford, UK, E-mail: moore.lim@unit.ox.ac.uk

***Received:** 19-May-2023, Manuscript No. AANN-23-99713; **Editor assigned:** 23-May-2023, Pre QC No. AANN-23-99713(PQ); **Reviewed:** 06-Jun-2023, QC No. AANN-23-99713; **Revised:** 12-Jun-2023, Manuscript No. AANN-23-99713(R); **Published:** 19-Jun-2023, DOI: 10.35841/aann-8.3.151*

***Citation:** Moore L. Health technology assessment of gene therapies for neuromuscular diseases. J NeuroInform Neuroimaging. 2023;8(3):151*

strength, function, and quality of life in patients with neuromuscular diseases. Safety assessments are essential to ensure that the potential risks associated with gene editing are carefully evaluated. Cost-effectiveness considerations are also crucial, as the high upfront costs of gene therapies need to be balanced against their potential long-term benefits. Through rigorous HTA, decision-makers can make informed choices about the adoption and reimbursement of gene therapies, ultimately improving the lives of individuals affected by neuromuscular diseases.

References

1. Abreu NJ, Waldrop MA. Overview of gene therapy in spinal muscular atrophy and duchenne muscular dystrophy. Pediatr Pulmonol. 2021;56(4):710-20.
2. Bulcha JT, Wang Y, Ma H, et al. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6(1):53.
3. Gonçalves E. Advanced therapy medicinal products: value judgement and ethical evaluation in health technology assessment. Eur J Health Econ. 2020;21(3):311-20.
4. Abou-El-Enein M, Grainger DW, Kili S. Registry contributions to strengthen cell and gene therapeutic evidence. Mol Ther. 2018;26(5):1172-6.
5. Paulk N. Gene therapy: It is time to talk about high-dose AAV: The deaths of two children with X-linked myotubular myopathy in the ASPIRO trial prompts a re-examination of vector safety. Genet Eng Biotechn N. 2020;40(9):14-6.

Citation: *Moore L. Health technology assessment of gene therapies for neuromuscular diseases. J NeuroInform Neuroimaging. 2023;8(3):151*